Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
161
days
Lung mucus burden and treatment response assessed by MRI in the post-modulator era
AuthorsAlexander M Matheson; Evan Prather; Matthew M Willmering; Jaime Mata; Giles Santyr; Felix A Ratjen; Elizabeth L Kramer; Zackary I Cleveland; Jason C Woods
AffiliationsCenter for Pulmonary Imaging Research, Cincinnati Children's Hospital, Cincinnati, OH, United States; Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH, United States; Department of Pediatrics, The University of Cincinnati, Cincinnati, OH, United States; College of Medicine, The University of Cincinnati, Cincinnati, OH, United States; University of Virginia, Virginia, VA, United States; Department of Radiology, The Hospital for Sick Children, Toronto, ON, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada
124
days
Expiratory lung MRI: a simple, sensitive method to quantify and visualise regional gas trapping in cystic fibrosis
AuthorsAmy V Simmons; Laurie J Smith; Zoe Somerville; Hannah Faulke; William Clark; David Hughes; Ina Aldag; Noreen West; Alberto M Biancardi; Jim M Wild; Neil J Stewart
AffiliationsPOLARIS, Division of Clinical Medicine, Faculty of Health, The University of Sheffield, United Kingdom; INSIGNEO Institute for in silico Medicine, The University of Sheffield, Sheffield, United Kingdom; Sheffield Children’s Hospital NHS Foundation Trust, Sheffield, United Kingdom
92
days
International Delphi consensus recommendations for the follow-up of children born to people with CF and exposed to CFTR modulators in utero or through breastfeeding; endorsed by the European Cystic Fibrosis Society
AuthorsIdan Bokobza; Traci M. Kazmerski; Louise Thomson; Rebecca V. Scott; Amy Downes; Claire L. Hogg; Siân Bentley; Elaine Bowman; Lynn Sinitsky; Olivia Beaumont; Ladina Weitnauer; Quitterie Reynaud; Philippe Reix; Imogen Felton; Jane C. Davies
AffiliationsImperial College London, Imperial Biomedical Research Centre, National Heart & Lung Institute, London, United Kingdom; Royal Brompton & Harefield Hospitals, part of Guys and St Thomas' Hospital NHS Foundation Trust, Department of Paediatric Respiratory Medicine, London, United Kingdom; University of Pittsburgh School of Medicine, Department of Pediatrics, Pittsburgh, United States; Royal Hospital for Children Glasgow, Department of Paediatric Respiratory Medicine, Glasgow, United Kingdom; Chelsea & Westminster Hospital, Department of Diabetes & Endocrinology, London, United Kingdom; Royal Brompton & Harefield Hospitals, part of Guys and St Thomas' Hospital NHS Foundation Trust, Adult Cystic Fibrosis Centre, London, United Kingdom; Imperial College London, Department of Metabolism, Digestion and Reproduction, London, United Kingdom; Royal Brompton & Harefield Hospitals, part of Guys and St Thomas' Hospital NHS Foundation Trust, Pharmacy Department, London, United Kingdom; West Hertfordshire Teaching Hospitals NHS Trust, Watford, United Kingdom; King's College Hospital, London, United Kingdom; Centre Hospitalier Universitaire Vaudois, Adult CF centre, Lausanne, Switzerland; Hospices Civils de Lyon – Hôpital Lyon Sud, Adult Cystic Fibrosis Center, Internal Medicine and Vascular Pathology Department, Lyon, France; University Claude Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), INSERM U1290, Lyon, France; Hospices civils de Lyon - Hôpital Femme Mère Enfant, Centre de ressources et de compétences pour la mucoviscidose, Lyon, France
110
days
Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patients
AuthorsAttilio Di Girolamo; Mattia Cristallo; Michelina Francesca Daddato; Federico Spataro; Giuseppina Leonetti; Pamela Vitullo; Eustachio Nettis
AffiliationsDepartment of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, Bari, Italy; Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Post Graduate School of Allergy and Clinical Immunology, Guido Baccelli Unit of Internal Medicine, University of Bari Aldo Moro, 70124 Bari, Italy; Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, 70124 Bari, Italy; Pediatric Cystic Fibrosis Centre, Azienda Universitaria Ospedaliera Consorziale Policlinico, Bari, Italy; Cystic Fibrosis Support Center, Ospedale G. Tatarella di Cerignola, Cerignola, Italy
151
days
Investigation of HE4 expression concerning epithelial-mesenchymal transition (EMT) in cystic fibrosis epithelial cells
AuthorsMarianna Pócsi; György Jázon Balla; Ferenc Fenyvesi; Ágnes Rusznyák; Zsolt Fejes; István Balogh; Milan Macek; Margarida D. Amaral; Béla Nagy
AffiliationsDepartment of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Department of Molecular and Nanopharmaceutics, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Department of Biology and Medical Genetics, 2nd Faculty of Medicine and Motol University Hospital, Charles University, Prague, Czech Republic; BioISI- Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal
203
days
Altered responsiveness to photic stimuli contribute to circadian disruption in cystic fibrosis
AuthorsDanica F. Patton-Parfyonov; Eden N. Kenner; Deborah A. Corey; Thomas J. Kelley; Rebecca Darrah
AffiliationsDepartment of Genetics and Genome Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH 44106
105
days
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis
AuthorsEva Van Braeckel; Andrew T. Braun; Nicholas J. Simmonds; Peter J. Barry; Jane C. Davies; Marie E. Egan; Allen Lapey; Marcus A. Mall; Edward F. McKone; Daniel Peckham; Marijke Proesmans; Bonnie Ramsey; Saioa Vicente Santamaria; Daniel Smith; Jennifer L. Taylor-Cousar; Elizabeth Tullis; Elke De Wachter; Nick Withers; Neil Ahluwalia; Sarah Conner; Mark Jennings; Yiyue Lou; Tanya G. Weinstock; Dominic Keating
AffiliationsDepartment of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; National Heart and Lung Institute, Imperial College London UK, Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust, London, UK; Manchester University NHS Foundation Trust, Manchester, UK; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; Yale University, New Haven, CT, USA; Massachusetts General Hospital, Boston, MA, USA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Lung Research (DZL), associated partner site, Berlin, Germany; German Center for Child and Adolescent Health (DZKJ), partner site Berlin, Berlin, Germany; Cluster of Excellence ImmunoPreCept, Charité - Universitätsmedizin Berlin, Berlin, Germany; St Vincent’s University Hospital, Dublin, Ireland; St James’s University Hospital, Leeds, UK; University Hospital of Leuven, Leuven, Belgium; Seattle Children’s Hospital, Seattle, WA, USA; Hospital Ramón y Cajal, Madrid, Spain; The Prince Charles Hospital, Brisbane, Queensland, Australia; National Jewish Health, Denver, CO, USA; St Michael’s Hospital, Toronto, Ontario, Canada; Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium; Royal Devon United Hospital NHS Foundation Trust, Exeter, UK; Vertex Pharmaceuticals Incorporated, Boston, MA, USA; Alfred Health, and Monash University, Melbourne, Victoria, Australia
91
days
Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis
AuthorsElias Seidl; Andrew Zikic; Srdjan Micic; Rianne de Vries; Julie Avolio; Alexander Moeller; Felix Ratjen; Hartmut Grasemann
AffiliationsDepartment of Respiratory Medicine, University Children's Hospital Zurich, Zurich, Switzerland; Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; Breathomix BV, Bargelaan 200, Leiden, CW 2333, The Netherlands; Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON M5G 1 × 8, Canada and University of Toronto, Toronto, Canada
225
days
Apical hyperosmotic challenge upregulates aquaporin-3 in human airway epithelia
AuthorsAlexander Sauter; Oliver H Wittekindt; Lara Gutjahr; Ronja Rössel; Manfred Frick; Sebastian FN Bode; Hanna Schmidt
AffiliationsInstitute of General Physiology, Ulm University; Albert-Einstein-Allee 11 89075, Ulm, Germany; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center; Eythstraße 24 89075, Ulm, Germany
40
days
Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy
AuthorsTimothy Riddles; Daniel Smith; David W Reid; Daniel Henderson; Arianne J Blanco; Vanessa Moore; Michelle Wood; Ieuan E S Evans
AffiliationsAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, QLD, Brisbane, Australia; Lung Inflammation & Infection, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Department of Microbiology, Royal Brisbane Women’s Hospital, Brisbane, QLD, Australia
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days